BFM
KRYS icon

Boothbay Fund Management’s Krystal Biotech KRYS Stock Holding History

Boothbay Fund Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,700
Closed -$1.78M – 1782
2024
Q2 		$1.78M Sell
9,700
-93,100
-91% -$15.6M 0.04% 539
2024
Q1 		$18.3M Buy
102,800
+3,600
+4% +$500K 0.35% 35
2023
Q4 		$12.3M Buy
99,200
+82,100
+480% +$9.1M 0.31% 47
2023
Q3 		$1.98M Buy
17,100
+15,200
+800% +$1.85M 0.05% 503
2023
Q2 		$223K Buy
+1,900
New +$194K ﹤0.01% 1440
2023
Q1 		– Sell
-31,000
Closed -$2.46M – 2342
2022
Q4 		$2.46M Buy
31,000
+14,100
+83% +$1.05M 0.06% 518
2022
Q3 		$1.18M Buy
+16,900
New +$1.22M 0.03% 797
2021
Q4 		– Sell
-28,900
Closed -$1.51M – 2058
2021
Q3 		$1.51M Buy
+28,900
New +$1.71M 0.04% 559

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's KRYS Position: Q1 2026 in Review

Boothbay Fund Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 3,527 shares — an estimated $870K sold.

Boothbay Fund Management first reported a position in KRYS in Q4 2018 and held it in 5 quarters. The position peaked at $1.57M in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Boothbay Fund Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 3,527 Krystal Biotech shares in Q1 2026, an estimated $870K.
  • Boothbay Fund Management first reported a position in Krystal Biotech in Q4 2018 and held it in 5 quarters.
  • Boothbay Fund Management's Krystal Biotech position peaked at $1.57M in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.